Lifeguard Ginsenoside Rh2 has an imprecise effect on cancer and is not routinely recommended. Ginsenoside Rh2 may improve the immunity of patients and indirectly inhibit the growth of tumor cells, but this mechanism of action is not clear, and there is no objective clinical and scientific research data to support the role of cancer treatment, so it does not belong to the normal means of treatment in the clinic. Cancer treatment has gradually entered the era of standardization, and there are standardized restrictions on various treatments and suitable groups of people, in order to enable patients to get the best treatment possible. Therefore, drugs and means of treatment outside the scope of normal treatment are not routinely recommended due to insufficient evidence. It is recommended that patients go to regular hospitals as soon as possible, standardized treatment, so as not to delay the disease.